Sj. Jubelirer et al., Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy, AM J HEMAT, 61(3), 1999, pp. 205-208
Platelets play a crucial role in the ischemic complications of percutaneous
coronary procedures. The recent availability of C7E3 Fab (Abxiximab or Reo
Pro(TM)), a chimeric monoclonal antibody Fab fragment directed against the
platelet glycoprotein IIb/IIIa receptor, has reduced abrupt closure and oth
er adverse events and lessened the need for revascularization procedures. A
s the use for this drug has increased, rare cases of severe thrombocytopeni
a have been revealed. From August 1995 to June 1997, 452 patients at Charle
ston Area Medical Center who underwent percutaneous coronary revascularizat
ion procedures and were treated with abciximab were evaluated for the devel
opment of severe thrombocytopenia (i.e., platelet count less than 20,000 wi
thin 48 hr of treatment). A review of published reports of severe thrombocy
topenia was also reviewed. A review of published reports of abciximab-induc
ed severe thrombocytopenia, as well as our three cases, reveals that: I)the
incidence is less than 0.7%; 2) the nadir platelet count (range 1,000-16,0
00) was noted within 2-31 hr after abciximab infusion; 3) the platelet coun
t increases to greater than 100,000 within 12 days in all patients; 4) blee
ding episodes were treated with platelet transfusion with an improvement in
platelet count within 24 hr in all patients in whom they were given; and 5
) in the one patient treated with gamma globulin alone, no significant rise
in platelet count was noted. Acute severe thrombocytopenia can occur after
ReoPro(TM) administration. Its development is not predictable and may occu
r within 2 hr of administration. Thrombocytopenia, therefore, requires cons
ideration in every patient treated with this drug. It appears prudent to ob
tain a platelet count 2 hr after initiating ReoPro(TM). If thrombocytopenia
develops, then the drug can be stopped in a timely manner and platelet tra
nsfusion can be given. Am, J, Hematol. 61: 205-208, 1999, (C) 1999 Wiley-Li
ss, Inc.